

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number

48-01032-01

Docket or Reference number

030-03416

CORRECTED COPY

Amendment No. 45

Wausau Hospital, Inc
Wausau Hospital Center
333 Pine Ridge Boulevard
Wausau, WI 54401

In accordance with letter dated July 3, 1985, License Number 48-01032-01 is amended as follows:

Conditions 12. and 20. are amended to read:

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

James M. Foerster, M.D.

Groups I, II, III, IV, V and VI
Xenon-133
In vitro studies

Jacob H. Martens, M.D.

Groups I, II, III, IV, V and VI
Xenon-133
In vitro studies

Donald M. Nowinski, M.D.

Groups I, II, III, IV, V and VI
Xenon-133
In vitro studies

G. H. Brister, M.D.

Groups I, II, III, IV and V
Xenon-133
In vitro studies

E. B. Koschmann, M.D.

Groups I, II and III
Xenon-133
In vitro studies

Henry Kanemoto, M.D.

Groups I, II and III
Xenon-133
In vitro studies

William Mahony, M.D.

Groups I, II and III
Xenon-133
In vitro studies

David Freeman, M.D.

Groups I, IV and V
Groups II and III limited to studies
of cardiac imaging and function

A. R. Bourque, M.D.

Group VI

Vina Luthra, M.D.

Groups I, II and III
Xenon-133
In vitro studies

8510030410 850919
REG3 LIC30
48-01032-01 PDR

COPY

2
me30

83 9/14/85

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number

48-01032-01

Docket or Reference number

030-03416

CORRECTED COPY

Amendment No. 45

Robert W. Mackie, M.D.

Groups II and III limited to studies
of cardiac imaging and function

Lawrence H. Schott, M.D.

Groups I, II and III
Xenon-133
In vitro studies

Philip R. Albert, M.D.

Groups I, II and III
Xenon-133
In vitro studies
Iodine-131 for treatment of
hyperthyroidism, cardiac
dysfunction and thyroid carcinoma

Richard D. Bartholomew, M.D.

In vitro studies

Guy W. Holmes, M.D.

In vitro studies

20. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated March 25, 1985; letters dated May 29, 1985 and July 3, 1985; and Model ALARA Program as contained in Appendix O of Regulatory Guide 10.8, October 1980. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

Condition 21. is added:

21. Notwithstanding Condition 18., the licensee may dispose of iodine-125 contaminated radioimmunoassay laboratory waste immediately if surveys as described in letter dated July 3, 1985 show no detectable contamination above background.

For the U.S. Nuclear Regulatory Commission

SEP 19 1985

Date _____

Original Signed
By James Mullauer
Materials Licensing Section, Region III

COPY